An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.

Results

Naziv:	An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
Autori :	Kim, Tae Won; ...; (broj, koautora 16)
Godina:	2016
Publikacija:	JOURNAL OF CLINICAL ONCOLOGY
ISSN:	0732-183X Journal of Clinical Oncology Pretraži identifikator
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 34 br. 4 str. 642-642
DOI:	10.1200/jco.2016.34.4_suppl.642
WoS-ID:	000378109600618
URI:	https://enauka.gov.rs/handle/123456789/820957
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

2
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall

Google Scholar^TM